Number of outstanding shares in Elekta AB
The increase of 730,769 new A-shares and 8,205 new B-shares is attributable to the conversion of shares within the framework of the 2012/17 convertible bond.
One A-share entitles the holder to ten votes and one B-share to one vote.
# # #
For further information, please contact:
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: email@example.com
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act The information was submitted for publication at 18:00 CET on April 28, 2017. (REGMAR)
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com